Skip to content
Cognoptix logo — The Eye Scan for Alzheimer's Early Insight

Cognoptix

The Eye Scan for Alzheimer's Early Insight

Founded 2019 United States Marlborough, United States 3 employees Venture round Total: $46.35M Biotechnology, Health Care +2

General Information

Company Name Cognoptix
Founded Year 2019
Location United States Marlborough, United States
Employees 3
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Cognoptix. To contact Cognoptix, visit cognoptix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cognoptix compare?

A PDF of Cognoptix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cognoptix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cognoptix

Cognoptix, established in 2019, is making strides in the Biotechnology and Medical Devices sectors with its innovative approach to identifying Alzheimer's disease (AD). The company's slogan, "The Eye Scan for Alzheimer's Early Insight," encapsulates its mission to provide a low-cost, practical, and non-invasive eye scan that detects beta-amyloid deposits in the lens. This biomarker can be identified years before it appears in the brain, offering a revolutionary early detection method for AD.

Headquartered in the United States, Cognoptix last secured a $2.60M Venture Round investment on 28 September 2020. Notable investors include New York Angels, Sidecar Fund2, LaunchPad Venture, and Harvard Business School Alumni Angels of Greater NY. This backing underscores investor confidence in Cognoptix's potential to transform AD diagnosis, presenting a compelling opportunity for stakeholders in Health Care and Health and Wellness.

Business keywords: Alzheimer's Disease, Early Detection Technology, Clinical Research, Innovation, Eye Technology, Medical Technology, Neurodegenerative Diseases, Diagnostics, Non-Invasive Testing, Amyloid Detection, Predictive Analytics, Healthcare Innovation, Optical Biomarkers, Preventive Healthcare

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.60M 4
New York Angels, Sidecar Fund2 +2
28 Sep 2020
Venture Round $1.30M 2
Nobska Point Capital, Alopexx
15 Dec 2019
Series D $15.00M 3
Inventages, LaunchPad Venture +1
30 Sep 2014
Debt Financing $390.00K 1
Maine Angels
24 Apr 2014
Series C $4.60M -
07 Jan 2011
Series B $18.50M 2
Inventages, Rockport Venture Partners
22 Oct 2008
Venture Round $1.60M -
20 Mar 2008
Series A $849.00K -
10 Jan 2008
Seed Round $1.01M 1
Roy Oron
22 Jan 2007
Angel Round $500.00K 5
Boston Harbor Angels, Maine Angels +3
23 Jan 2006

Cognoptix Alternatives & Competitors

View All Alternatives
Cognoptix vs

Advancing Therapeutics and Diagnostics for Amyloid Diseases Since 1996

Venture round
2-10 employees
Biotechnology, Health Care
Cognoptix vs

Identification of an early Alzheimer's disease will accelerate the identification of curative drugs

Venture round
13 employees
Biotechnology, Health Care
Cognoptix vs

Restoring clarity in amyloid diseases

Grant
11 employees
Biotechnology, Health Care

FAQ About Cognoptix

The Eye Scan for Alzheimer's Early Insight
Cognoptix was founded in 2019.
Cognoptix is headquartered in Marlborough, United States.
Cognoptix operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on Alzheimer's Disease, Early Detection Technology, Clinical Research and Innovation.
Cognoptix has approximately 3 employees.
Cognoptix has completed 10 funding rounds, raising a total of $46.35M. The latest funding stage is Venture round.
Top alternatives and competitors to Cognoptix include ProteoTech, ADmit Therapeutics, Amyl Therapeutics, EyeMove, Neurotrope Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cognoptix and ProteoTech are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cognoptix, https://www.bouncewatch.com/company/cognoptix, updated 30 July 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout